Kafaffen ƙaddar da ƙwayoyin maganin ƙwayoyi suna ba da kyauta sau ɗaya-Daily, Single-Pill Far
Ƙayyadewa
Ƙarshe shi ne kwamfutar hannu guda ɗaya, mai amfani da maganin maganin cutar HIV, wanda ya kunshi nau'o'i daban-daban daban daban daban daban:
- rilpivirine , wanda ba shi da magungunan baya wanda ya hana shi (NNRTI)
- emtricitabine, mai ƙwayar magungunan ƙaddamar da ƙwayar cuta ta tsakiya (NtRTI)
- tenofovir disoproxil fumarate (TDF), wani NtRTI
Cibiyar Abinci da Harkokin Kiwon Lafiyar Amurka (FDA) ta amince da ita a ranar 10 ga watan Agustan shekara ta 2011, don amfani da duka yara da yara fiye da shekaru 12 da basu taba yin cutar kanjamau ba , wadanda suke da nauyin hoto na kwayoyin kwayoyi 100,000 ko m. , kuma ku auna kilogram 35 (35kg) ko fiye.
Ana iya amfani da ita don maye gurbin farfadowa na yanzu idan mai haƙuri ya sami nauyin hoto mai ban tsoro (
Halitta
Ƙarshe shi ne ruwan hoda, nau'i mai nauyin kambi, mai kwakwalwar fim, wanda ya hada da 25mg na rilpivirine, 200mg na emtricitabine da 300mg na TDF. An sanya shi da "GSI" a gefe ɗaya kuma ya bayyana a daya.
Yankewa
Ɗaya daga cikin kwamfutar hannu yau da kullum da aka ci tare da abinci. Ba za a dauka cikakke ba tare da wasu magungunan ƙwayar cutar da ke amfani da cutar HIV.
Hanyoyin Gaba
An gano wasu alamun maganin miyagun ƙwayoyi a cikin jarrabawar gwaji da ke dauke da cikakke, wanda mafi yawan su sune:
- Jiɗa
- Ciwon kai
- Insomnia
- Dama
Hanyoyin da ke faruwa a kullum sun wuce, tare da ƙananan marasa lafiya sun daina sakamakon rashin haƙuri.
Contraindications
Ba za a dauka cikakke tare da wasu kwayoyi ko kari ba:
- Magunguna masu guba: Tegretol, Trilepta, phenobarbital, phenytoin
- Tarin maganin tarin fuka: Mycobutin, Rifater, Rifamate, Rimactane, Rifadin, Priftin
- Proton pump inhibitors (PPIs): Nexium, Kapidex, Dexilant, Prevacid, Losec, Prilosec, Protonix, Aciphex ko wani PPI
- Magungunan kwayar cutar: dexamethasone (ko da yake ana iya gudanar da ita a cikin kashi guda idan an nuna ta da lafiya)
- St. John's Wort
Koyaushe sanar da likitanka game da duk wani magani ko kari, wanda aka tsara ko ba a ba shi ba, wanda za ka iya ɗauka kafin ka fara wani maganin antiretroviral.
Sauran Bayanai
Ba a bada cikakkiyar bayani ga marasa lafiya da rashin nauyin koda (wanda aka kiyasta yana da ƙayyadadden ƙwayar halitta daga ƙasa da 30mL a minti daya). Don Allah a ba da shawara ga likitanku idan an kasance ko an kula da ku saboda kowace cuta ta koda ta wani likita.
Ba a bada shawara ga marasa lafiya tare da rashin hanta ko kuma wadanda ke fama da ciwon hawan B (HBV) na kullum kamar yadda zai iya haifar da matsalolin hanta. Ana ba da shawara cewa mutane da ke dauke da kwayar cutar ta HIV za su kasance masu kariya ga HBV kafin su tsara cikakken. Don Allah a ba da shawara ga likitanku idan kuna da kowace matsalar hanta da / ko tarihin hepatitis.
Hanyoyin rilpivirine na Complera na iya haifar da cututtuka a cikin ƙananan marasa lafiya, sau da yawa a cikin nau'i mai laushi, ƙurar ido ("launin ruwan hoda"), fatar ido, zazzabi, ko sauran amsa masu rashin lafiyar. Yawancin lokaci, halayen kamuwa da cututtuka ba zai wuce makonni shida ba bayan ya fara farfadowa. Sanar da likitanku nan da nan daga kowane irin alamun bayyanar ya bayyana. A cikin lokuta masu tsanani, za a iya dakatar da farfadowa.
Jiyya Update
An amince da FDA a ranar 1 ga watan Maris, 2016, wanda ya samo asali daga sunan Odefsey . Wannan sabon tsari ya maye gurbin takaddun TDF tare da miyagun ƙwayoyi da ake kira tenofovir alafenamide (TAF), wanda aka ƙaddamar da shi a matsayin magunguna.
Ba kamar TDF ba, TAF ba shi da magungunan aiki amma ya yi amfani da maganin ta jiki don canza shi a cikin tsari. Don haka, ana amfani da miyagun ƙwayoyi fiye da yadda ya kamata a cikin kwayoyin halitta a ƙananan canje-canje, kazalika da mummunan ƙwayar magungunan ƙwayoyi (musamman a game da matsalar rashin ƙarfi da aka haɗa da TDF).
Sources:
Cibiyar Abinci da Drugura ta Amurka (FDA_ "Amincewa da Ƙarshe: Hannun da ake amfani da su a lokacin da ake amfani da su." Silver Srping, Maryland; An bayar da Agusta 10, 2011.
Kimiyya ta Gilead. "Karshe - Ƙarin Bayani na Bayani Bayanan." Foster City, California; isa ga Maris 18, 2016.
Reuters. "BRIEF - Kimiyya ta Gilead ta ce FDA ta amince da Odefsey" An yi bikin Maris 1, 2015.